Expression of GLUT-1 and transglutaminase 2 is increased in aggressive breast cancer, whereas claudin-1, which is expressed in normal tissues, is absent in such tumors. This experimental study was undertaken to establish the aggressiveness and prognosis of DMBA-induced mammary tumors in female Wistar rats based on the assessment of these markers.
Materials and methods
The rats were divided into two groups, a control group (n = 70) and a chemoprevention group (n = 70). Breast tumors were induced in both groups by administration of 7,12-dimethylbenz[a]anthracene (DMBA). The chemoprevention group also received alpha-tocopherol and a solution of micronutrients containing ascorbic acid and selenium. Neoplastic lesions of both groups were randomly selected for immunohistochemical assessment of the expression of GLUT-1, transglutaminase 2 and claudin-1.
Results
A higher proportion of mammary tumors expressed GLUT-1 and transglutaminase 2 in the chemoprevention group. Claudin-1 expression was absent in all tumors of both groups.
Conclusions
These results are suggestive of increased aggressiveness of tumors not susceptible to chemoprevention by the agents used in this study.
DiasM., CabritaS., SousaE., FrançaB., PatrícioJ., OliveiraC.: Benign and malignant mammary tumors induced by DMBA in female Wistar rats. Eur J Gynaec Oncol, 20: 285–288, 1999.
2.
DiasM.F., SousaE., CabritaS., PatrícioJ., OliveiraC.F.: Chemoprevention of DMBA-induced mammary tumors in rats by combined regimen of alpha-tocopherol, selenium and ascorbic acid. Breast J, 6: 14–19, 2000.
3.
MiddletonP.J.: The histogenesis of mammary tumors induced in the rat by chemical carcinogens. Br J Cancer, 19: 830–839, 1965.
4.
GeyerR.P., BleishV.R., BryantJ.E., RobbinsA.N., SaslawI.M., StareF.J.: Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-1, 2-benzanthracene. Cancer Res, 11: 474–478, 1951.
5.
RussoJ., RussoI.H.: Susceptibility of the mammary gland to carcinogenesis. Am J Pathol, 100: 497–512, 1980.
6.
MedinaD.: The mammary gland: a unique organ to the study of development and tumorigenesis. J Mammary Gland Biol Neoplasia, 1: 5–19, 1996.
7.
RussoJ., GustersonB.A., RogersA.E., RussoI.H., WellingsS.R., van ZwietenM.J.: Comparative study of human and rat tumorigenesis. Lab Invest, 62: 244–278, 1990.
8.
IssacsJ.T.: Genetic control of resistance to chemically-induced mammary adenocarcinogenesis in the rat. Cancer Res, 46: 3958–3963, 1986.
9.
RussoJ., RussoI.H.: Biological and molecular bases of mammary carcinogenesis. Lab Invest, 57: 112–137, 1987.
10.
KallmanR.F.: Rodent tumor models in experimental cancer therapy, 12th ed, Pergamon, New York, 1987.
11.
HsuL.C., KennanW.S., ShepelL.A., JacobH.J., SzpirerC., SzpirerJ., LanderE.S., GouldM.N.: Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene. Cancer Res, 54: 2765–2770, 1994.
12.
WelshC.W.: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas. A review and tribute to Charles Brenton Huggins. Cancer Res, 45: 3415–3443, 1985.
13.
RussoJ., TayL.K., RussoI.H.: Differentiation of mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat, 2: 5–73, 1982.
14.
RussoJ., SabyJ., IsenbergW.M., RussoI.H.: Pathogenesis of mammary carcinomas induced in rats by 7,12-dimethylbenz[a]anthracene. J Natl Cancer Inst, 59: 435–445, 1977.
15.
RussoI.H., RussoJ.: Developmental stage of the rat mammary gland as a determinant of its susceptibility to 7,12-dimethylbenz[a]anthracene. J Natl Cancer Inst, 61: 1439–1449, 1978.
16.
HaslamS.Z.: The effect of age on the histopathogenesis of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the Lewis rat. Inst J Cancer, 26: 349–356, 1980.
17.
NagasawaH., YanaiR.: Frequency of mammary cell division in relation to age: its significance in the induction of mammary tumors by carcinogen in rats. J Natl Cancer Inst, 52: 609–610, 1974.
18.
DaoT.L.: Mammary cancer induction by 7,12-dimethylbenz[a]anthracene. Relation to age. Science, 165: 810–811, 1969.
19.
ThordarsonG., JinE., GuzmanR.C., SwansonS.M., NandiS., TalamantesF.: Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia?Carcinogenesis, 16: 2847–2853, 1995.
20.
RussoJ., RussoI.H., IrelandM., SabyJ.: Increased resistance of multiparous rat mammary gland to neoplastic transformation by DMBA. Proc Am Assoc Cancer Res, 18: 149, 1977.
21.
MoonR.C.: Relationship between previous reproductive history and chemical mammary cancer in rats. Inst J Cancer, 4: 312–317, 1969.
22.
SinhaD.K., PazikJ.E., DaoT.L.: Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. Br J Cancer, 57: 390–397, 1988.
23.
SylvesterP.W., AylsworthC.F., Van VugtD.A., MeitesJ.: Effects of alterations in early hormonal dependency of carcinogen-induced mammary tumors in rats. Cancer Res, 43: 5342–5346, 1983.
24.
CioccaD.R., ParenteA., RussoJ.: Endocrinologic milieu and susceptibility of the rat mammary gland to carcinogenesis. Am J Pathol, 109: 47–56, 1982.
25.
HugginsC., GrandL.C., BrillantesF.P.: Mammary cancer induced by single feeding of polynuclear hydrocarbons and its suppression. Nature, 189: 204–207, 1961.
26.
GullinoP.M., PettigrewH.M., GranthamF.H.: N-nitrosomethylurea as mammary carcinogen in rats. J Natl Cancer Inst, 54: 401–414, 1975.
27.
JanssD.H., MoonR.C., IrvingC.C.: The binding of 7,12-dimethylbenz[a]anthracene to mammary parenchyma DNA and protein in vivo. Cancer Res, 32: 254–258, 1972.
28.
IpC., VadhanavikitS., GantherH.: Cancer chemoprevention by aliphatic selenocyanates: effect of chain length on inhibition of mammary tumors and DMBA adducts. Carcinogenesis, 16: 35–38, 1995.
29.
NoguchiM., MinamiM., YagasakiR., KinoshitaK., EarashiM., KitagawaH., TaniyaT., MiyasakiI.: Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low dose EPA and DHA. Br J Cancer, 75: 348–353, 1997.
30.
IpC., LiskD.J., ThompsonH.J.: Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis, 17: 1979–1982, 1996.
31.
El-SohemyA., BruceW.R., ArcherM.C.: Inhibition of rat mammary tumorigenesis by dietary cholesterol. Carcinogenesis, 17: 159–162, 1996.
32.
BaumA., MevissenM., KaminoK., MohrU., LoscherW.: A histopathological study on alterations in DMBA-induced mammary carcinogenesis in rats with 50 Hz, 100 μT magnetic field exposure. Carcinogenesis, 16(1): 119–126, 1995.
33.
IpC., LiskD.J.: Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the actin of selenium. Carcinogenesis, 16: 2649–2652, 1995.
34.
WuL., McgarryL., LanfearJ., HarrisonP.R.: Altered selenium-binding protein levels associated with selenium resistance. Carcinogenesis, 16(11): 2819–2824, 1995.
35.
GarlandM., MorrisJ.S., StampferM.J.: Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst, 87(7): 497–505, 1995.
36.
HarmanD.: Dimethylbenz[a]anthracene induced cancer: inhibitory effect of dietary vitamin E. Clin Res, 17: 125–129, 1969.
37.
IpC., LiskD.J.: Characterization of tissue selenium profiles and anticarcinogenic responses in rats fed natural sources of selenium-rich products. Carcinogenesis, 15(4): 573–576, 1994.
38.
ThompsonH.J., WilsonA., LuJ., SinghM., JiangC., UpadhyayaP., el-BayoumyK., IpC.: Comparison of the effects of an organic and inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis, 15: 183–186, 1994.
39.
IpC., IpM.M.: Chemoprevention of mammary tumorigenesis by a combined regimen of selenium and vitamin A. Carcinogenesis, 2: 915–918, 1981.
IpC., GantherH.E.: Activity of methylated forms of selenium in cancer prevention. Cancer Res, 50: 1206–1211, 1990.
42.
IpC.: Prophylaxis of mammary neoplasia by selenium supplementation in the initiation and promotion phase of chemical carcinogenesis. Cancer Res, 41: 4386–4390, 1981.
43.
MedinaD., ShepherdF.: Selenium-mediated inhibition of mouse mammary tumorigenesis. Cancer Lett, 8: 241–245, 1980.
44.
LiuJ., GilbertK., ParkerH.M., HaschekN.M., MilnerJ.A.: Inhibition of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and DNA adducts by dietary selenite. Cancer Res, 51: 4613–4617, 1991.
45.
El-BayoumyK.: Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis, 15: 2395–2429, 1994.
46.
NovotnyJ.A., MilnerJ.A.: Impact of ascorbic acid on selenium-induced growth inhibition of canine mammary tumor cells in vitro. J Nutr Biochem, 4: 341–345, 1993.
47.
HovarthP., IpC.: Synergistic effect of vitamin E and selenium in chemoprevention of mammary carcinogenesis in rats. Cancer Res, 43: 5335–5341, 1983.
48.
IpC., El-BayoumyK., UpadhyayaP., GantherH., VadhanavikitS., ThompsonH.: Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis, 15: 187–192, 1994.
49.
TakadaH., HirookaT., HatanoT., HamadaY., YamamotoM.: Inhibition of 7,12-dimethylbenz[a]anthracene-induced lipid peroxidation and mammary tumor development in rats by vitamin E in conjunction with selenium. Nutr Cancer, 17: 115–122, 1992.
50.
IpC.: Dietary vitamin E intake and mammary carcinogenesis in rats. Carcinogenesis, 3: 1453–1456, 1982.
51.
LiJ., ShiM., CaoY., YuanW., PangT., LiB., SunZ., ChenL., ZhaoR.C.: Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun, 342: 1341–1351, 2006.
52.
StackhouseB.L., WilliamsH., BerryP., RusselG., ThompsonP., WinterJ.L., KuteT.: Measurement of Glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat, 93: 247–253, 2005.
53.
VleugelM.M., GreijerA.E., ShvartsA., van der GroepP., van BerkelM., AarbodemY., van TinterenH., HarrisA.L., van DiestP.J., van der WallE.: Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol, 58: 172–177, 2005.
54.
MehtaK., FokJ., MillerF.R., KoulD., SahinA.A.: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res, 10: 8068–8076, 2004.
55.
AntonyakM.A., MillerA.M., JansenJ.M., BoehmJ.E., BalkmanC.E., WakshlagJ.J., PageR.L., CerioneR.A.: Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem, 279: 41461–41467, 2004.
56.
JiangW.G., AblinR., Douglas-JonesA., ManselR.E.: Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep, 10: 2039–2044, 2003.
57.
YamaguchiH., WangH.G.: Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol, 26: 569–579, 2006.
58.
ResnickM.B., KonkinT., RouthierJ., SaboE., PricoloV.E.: Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol, 18: 511–518, 2005.
59.
ResnickM.B., GavilanezM., NewtonE., KonkinT., BhattacharyaB., BrittD.E., SaboE., MossS.F.: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol, 36: 886–892, 2005.
60.
TókésA.M., KulkaJ., PakuS., SzikA., PáskaC., NovákP.K., SzilákL., KissA., BogiK., SchaffZ.: Claudin-1, −3 and −4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res, 7: 296–305, 2005.
61.
MartinsF.C., TeixeiraF., ReisI., GeraldesN., CabritaS., DiasM.F.: Chemoprevention and mammary neoplastic aggressiveness. Breast J, 14: 608–609, 2008.
62.
StramD.O., WuA.H.: Beta-carotene and lung cancer: A lesson for future chemoprevention investigations?J Natl Cancer Inst, 95: E4, 2003.
63.
GoodmanG.E., ThornquistM.D., BalmesJ., CullenM.R., MeyskensF.L.Jr., OmennG.S., ValanisB., WilliamsJ.H.: The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst, 96: 1743–1750, 2004.
64.
VirtamoJ., PietinenP., HuttunenJ.K., KorhonenP., MalilaN., VirtanenM.J., AlbanesD., TaylorP.R., AlbertP.: ATBC Study Group. The ATBC Study Group: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA, 290: 476–485, 2004.
65.
AfifyA., ZhouH., HowellL., PaulinoA.F.: Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol, 49: 621–626, 2005.
66.
BrownR.S., LeungJ.Y., FisherS.J., FreyK.A., EthierS.P., WahlR.L.: Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med, 37: 1042–1047, 1996.
67.
OzbudakI.H., KaraveliS., SimsekT., ErdoganG., PestereliE.: Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol, 108: 603–608, 2008.
68.
MoadelR.M., WeldonR.H., KatzE.B., LuP., ManiJ., StahlM., BlaufoxM.D., PestellR.G., CharronM.J., DadachovaE.: Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res, 65: 698–702, 2005.
69.
EnglesJ.M., QuarlessS.A., MamboE., IshimoriT., ChoS.Y., WahlR.L.: Stunning and its effect on H-FDG uptake and gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med, 47: 603–608, 2006.
70.
GrigorievM.Y., SuspitsinE.N., TogoA.V., PozharisskiK.M., IvanovaO.A., NardacciR., FalascaL., PiacentiniM., ImyanitovE.N., HansonK.P.: Tissue transglutaminase expression in breast carcinomas. J Exp Clin Cancer Res, 20: 265–268, 2001.
71.
MirshraS., MurphyL.J.: Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase II as an insulin-like growth factor-binding protein-3 kinase. J Biol Chemistry, 279: 23863–23868, 2004.
72.
VermaA., MehtaK.: Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets, 7: 559–565, 2007.
73.
AiL., KimW.J., DemircanB., DyerL.M., BrayK.J., SkehanR.R., MassollN.A., BrownK.D.: The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis, 29: 510–518, 2008.
74.
BoehmJ.E., SinghU., CombsC., AntonyakM.A., CerioneR.A.: Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem, 277: 20127–20130, 2002.
75.
ChenJ.S., AgarwalN., MehtaK.: Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat, 71: 237–247, 2002.
76.
VäreP., LoikkanenI., HirvikoskiP., VaaralaM.H., SoiniY.: Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep, 19: 25–33, 2008.
77.
HigashiY., SuzukiS., SakaguchiT., NakamuraT., BabaS., ReineckerH.C., NakamuraS., KonnoH.: Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res, 139: 68–76, 2007.
78.
HoevelT., MacekR., SwisshelmK., KubbiesM.: Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids. Int J Cancer, 108: 374–383, 2004.
79.
HoevelT., MacekR., MundiglO., SwisshelmK., KubbiesM.: Expression targeting of the tight junction protein CLDN-1 in CLDN1-negative human breast tumor cells. J Cell Physiol, 191: 60–68, 2002.
80.
TroskoJ.E.: The role of stem cells and gap junctional intercellular communication in carcinogenesis. J Biochem Mol Biol, 36: 43–48, 2003.
81.
Al-HajjM., WichaM.S., Benito-HernandezA., MorrisonS.J., ClarkeM.F.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100: 3983–3988, 2003.
82.
TaiM.H., ChangC.C., KiupelM., WebsterJ.D., OlsonL.K., TroskoJ.E.: Oct-4 expression in adult stem cells: evidence in support of the support of the stem cell theory of carcinogenesis. Carcinogenesis, 26: 495–502, 2005.
83.
WebsterJ.D., Yusbasiyan-GurkanV., TroskoJ.E., ChangC.C., KiupelM.: Expression of the embryonic transcription factor Oct4 in canine neoplasms: a potential marker for stem cell subpopulations in neoplasia. Vet Pathol, 44: 893–900, 2007.
84.
AtlasiY., MowlaS.T., ZiaeeS.A., BahramiA.R.: Oct-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer, 120: 1596–1602, 2007.
85.
CerrutiP.A.: Prooxidant states and tumor promotion. Science, 227: 375–347, 1985.
86.
DevarajanE., ChenJ., MultaniA.S., PathakS., SahinA.A., MehtaK.: Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol, 20: 913–920, 2002.
